Patients who received SBRT plus pembrolizumab and trametinib achieved a median overall survival (OS) of 24.9 months (95% CI, 23.3-26.5) compared with SBRT plus gemcitabine (Gemzar), which yielded a median OS of 22.4 months (95% CI, 0.44-0.82; HR, 0.60; 95% CI, 0.44-0.83; P = .0012). Investigators emphasize that a phase 3 trial is still needed in order to confirm the findings. The 2-year OS rate in the SBRT plus gemcitabine was 37.6% (95% CI, 32.3%-42.9%) and 56.5% (95% CI, 51.1%-61.9%) for the SBRT plus pembrolizumab and trametinib group. Read more . . .
The use of stereotactic body radiotherapy (SBRT) plus pembrolizumab (Keytruda) and trametinib (Mekinist) could be a potential novel treatment for patients with recurrent pancreatic cancer after surgery, according to the results of a phase 2 (NCT02704156) study published in Lancet Oncology.